Tasimelteon: A Melatonin Receptor Agonist for Non-24-Hour Sleep-Wake Disorder

Annals of Pharmacotherapy

Volumn 48, Issue 12, 2014, Pages 1636-1641

  Johnsa, Jessica D ^a   Neville, Michael W ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

melatonin; Non 24; ramelteon; tasimelteon

Indexed keywords

ALANINE AMINOTRANSFERASE; MELATONIN RECEPTOR; PLACEBO; TASIMELTEON; BENZOFURAN DERIVATIVE; CYCLOPROPANE DERIVATIVE;

AREA UNDER THE CURVE; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; DAYTIME SOMNOLENCE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NIGHTMARE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SLEEP TIME; SLEEP WAKING CYCLE; SOMNOLENCE; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; AGONISTS; DRUG EFFECTS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

BENZOFURANS; CIRCADIAN RHYTHM; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPROPANES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, MELATONIN; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84921483847     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014550476     Document Type: Review

References (24)

1. Dhillon S,Clarke M.Tasimelteon: first global approval.Drugs. 2014;74:505-511
2. DressmanMLicameleLFeeneyJPolymeropolousM. Seventy percent of totally blind people with sleep complaints are not entrained to the 24 hour clock. http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDcwMDg3fENoaWxkSUQ9NTAwNzU2fFR5cGU9MQ==&t=1. Accessed March 5, 2014.
3. Vanda Pharmaceuticals. NCT01163032: a multicenter, randomized, double-mask, placebo-controlled, parallel study to investigate the efficacy and safety of 20mg tasimelteon versus placebo in totally blind subjects with N24HSWD followed by an OLE phase. https://clinicaltrials.gov/ct2/show/NCT01163032?term=NCT01163032&rank=1. Accessed August 28, 2014.
4. American Academy of Sleep Medicine. Circadian rhythm sleep disorders. http://www.aasmnet.org/resources/fact-sheets/crsd.pdf. Accessed February 10, 2014.
5. Uchiyama M,Lockley SW.Non–24-hour sleep-wake syndrome in sighted and blind patients.Sleep Med Clin. 2009;4:195-211
6. National Sleep Foundation. Non-24-hour sleep wake disorder treatment and care. http://non24.sleepfounda-tion.org/treatment.html. Accessed February 12, 2014.
7. Circadian Sleep Disorders Network. Treatment for delayed sleep phase and non-24. http://www.circadiansleep-disorders.org/treatments.php. Accessed February 11, 2014.
8. National Center for Complementary and Alternative Medicine. Melatonin: what you need to know. http://nccam.nih.gov/health/melatonin. Accessed May 8, 2014.
9. US Pharmacopeil Convention. USP verified dietary supplements. http://www.usp.org/usp-verification-services/usp-verified-dietary-supplements. Accessed March 10, 2014.
10. Rajaratnam SMW,Polymeropoulos MH,Fisher DM, et al.Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.Lancet. 2009;373:482-491
11. Deerfield, IL: Takeda Pharmaceuticals America; 2010:
12. Nomura T,Kawase S,Watanabe Y,Nakashima K.Use of ramelteon for the treatment of secondary REM sleep behavior disorder.Intern Med. 2013;52:2123-2126
13. Norris ER,Burke K,Correll JR, et al.A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder.J Affect Disord. 2013;144:141-147
14. Liu J,Wang LN.Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis.Int J Clin Pract. 2012;66:867-873
15. Greenwood Village, CO: Truven Health Analytics; 2014:
16. Washington, DC: Vanda Pharmaceuticals; 2014:
17. Hardeland R.Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.Curr Opin Investig Drugs. 2009;10:691-701
18. Neubauer DN.A review of ramelteon in the treatment of sleep disorders.Neuropsychiatr Dis Treat. 2008;4:69-79
19. Hardeland R.New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.Neuropsychiatr Dis Treat. 2009;5:341-354
20. Vanda Pharmaceuticals. Tasimelteon advisory committee meeting briefing materials 14 November 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterialsDrugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM374388.pdf. Accessed July 16, 2014.
21. Vanda Pharmaceuticals. NCT01429116: tasimelteon for the treatment of non-24 sleep-wake disorder (N24SWD) in blind individuals with no light perception. https://clinicaltrials.gov/ct2/show/NCT01429116?term=NCT01429116&rank=1. Accessed August 28, 2014.
22. Vanda Pharmaceuticals. NCT01218789: tasimelteon for the treatment of non-24 sleep-wake disorder (N24SWD) in blind individuals with no light perception. https://clinicaltrials.gov/ct2/show/NCT01218789?term=NCT01218789&rank=1. Accessed August 28, 2014.
23. Sack RL,Lewy AJ,Blood ML,Keith LD,Nakagawa H.Circadian-rhythm abnormalities in totally blind people: incidence and clinical-significance.J Clin Endocrinol Metab. 1992;75:127-134
24. FDA Press Release. FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in blind individuals. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm384092.htm. Accessed May 12, 2014.